Drug recall · June 17, 2026
DOXOrubin Hydrochloride Liposome injection recall
Why: Presence of Particulate matter: Particulate matter identified as glass.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), 25 mL single-dose vials, Sterile, Rx only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol, Gujarat, India, NDC 72603-200-01.
- Lots / codes
Lot HAG2581B, expires: 05/31/2027
- Quantity
- 675 vials
- Company
- Sun Pharmaceutical Industries Inc, Princeton, NJ
- Distribution
- U.S. Nationwide
- Initiated
- May 12, 2026 · Voluntary: Firm initiated
- Classified
- June 5, 2026
- Reported
- June 17, 2026
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Doxorubicin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.